Location History:
- Honolulu, HI (US) (1999)
- San Antonio, TX (US) (2002 - 2019)
- Austin, TX (US) (2020)
Company Filing History:
4 out of 265 
4 out of 5,450 
2 out of 10 
Years Active: 1999-2020
Title: The Innovative Contributions of Susan L. Mooberry in Cancer Research
Introduction: Susan L. Mooberry, a prominent inventor based in San Antonio, TX, has made significant strides in the field of cancer research. With a remarkable portfolio of 11 patents, her work focuses on the development of novel treatment methods for Ewing family tumors and microtubule stabilizers, contributing vitally to the advancement of medical science.
Latest Patents: Among her latest innovations is the patent for "Altertoxin II as a selective inhibitor of Ewing family of tumor cells". This invention outlines methods for treating Ewing family tumors (EFT) through the administration of altertoxin II to affected subjects. Another significant patent is for "Taccalonolide microtubule stabilizers", which involves epoxytaccalonolide as an anti-proliferative microtubule stabilizing agent. These advancements represent critical progress in targeted cancer therapies.
Career Highlights: Susan has worked with esteemed institutions such as the University of Hawai'i and the University of Texas System, where her research and patent work have been integral to developing new treatment methodologies for cancer. Her experience within these academic frameworks has allowed her to translate research into practical medical applications.
Collaborations: Throughout her career, Susan has collaborated with notable colleagues, including April L. Risinger and Pemmaraju Narasimha Rao. These partnerships have fostered an environment of innovation, leading to successful patent applications and furthering the impact of her research in the scientific community.
Conclusion: Susan L. Mooberry stands out as an influential inventor whose contributions to cancer research have the potential to change lives. Through her innovative patents and collaborative efforts, she continues to pioneer advancements in treatments for Ewing family tumors and microtubule stabilization, solidifying her status as a leader in her field.